Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2006

View Archived Issues

Promising preclinical results reported on Seikagaku's novel cathepsin K inhibitor

Study provides clues on the hypoglycemic action of novel KATP channel modulator

ALX-0081, a Nanobody targeting the von Willebrand Factor, yields positive preclinical results

Clinical study of BIBT-986 in healthy volunteers gives favorable results

Novel bioactive natural products presented at the Medicinal Chemistry Symposium

MM-101 ameliorates vesical dysfunction in diabetes model

Fuso signs new license agreement for OTS-102 for additional indication

PhytoMedical to expedite development of polyphenolic compounds for diabetes

Enrollment under way in phase IIb study of P1A

FTC clears Abbott's acquisition of Kos

Nastech updates status of PTH1-34 Nasal Spray program

Malaria Vaccine Technology Roadmap launched

Combidex filed for approval in E.U.

Fast track designations for ipilimumab in metastatic melanoma

Recent Valeant patent reports novel HIV reverse-transcriptase inhibitors

Novel agents for thrombotic disorders disclosed in recent patents

Recent patents describe new agents with potential as cardiovascular disorder treatments

IND filed for LX-1031 for gastrointestinal disorders

Tripep seeks to begin phase I study of ChronVac-C delivered with electroporation

Recent Novartis and Almirall patents describe new therapeutic agents for respiratory disorders

ReNeuron files IND for ReN-001 stem cell therapy for stroke

Novel antibacterial drugs disclosed in recent patents

New phase IIa study evaluates PRX-03140 in mild Alzheimer's disease

ReQuip launched for Parkinson's disease in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...